Ipsen is buying U.S. blood cancer startup Kartos for up to $1.75 billion
Colleen Cabi
·
2026-06-29
·
via Quartz
The French drugmaker is paying $450 million upfront for Kartos, which is developing a late-stage myelofibrosi…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。